O
OLEMA PHARMACEUTICALS INC
NASDAQ: OLMA (Olema Pharmaceuticals, Inc.)
Last update: 6 hours ago4.69
0.50 (11.93%)
| Previous Close | 4.19 |
| Open | 4.23 |
| Volume | 996,576 |
| Avg. Volume (3M) | 890,017 |
| Market Cap | 320,895,872 |
| Price / Book | 0.840 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Diluted EPS (TTM) | -2.00 |
| Total Debt/Equity (MRQ) | 0.30% |
| Current Ratio (MRQ) | 15.22 |
| Operating Cash Flow (TTM) | -124.83 M |
| Levered Free Cash Flow (TTM) | -70.86 M |
| Return on Assets (TTM) | -27.44% |
| Return on Equity (TTM) | -41.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Olema Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
1.9
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 0.5 |
| Average | 1.88 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.32% |
| % Held by Institutions | 98.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 31 Mar 2025 | 6,843,954 |
| Paradigm Biocapital Advisors Lp | 31 Mar 2025 | 6,741,172 |
| Deep Track Capital, Lp | 31 Mar 2025 | 3,442,833 |
| Logos Global Management Lp | 31 Mar 2025 | 3,208,875 |
| Mpm Bioimpact Llc | 31 Mar 2025 | 2,930,446 |
| Lightspeed Management Company, L.L.C. | 31 Mar 2025 | 1,930,894 |
| Pictet Asset Management Holding Sa | 31 Mar 2025 | 1,879,013 |
| Vivo Capital, Llc | 31 Mar 2025 | 1,505,862 |
| Woodline Partners Lp | 31 Mar 2025 | 1,477,907 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (HC Wainwright & Co., 539.66%) | Buy |
| Median | 25.00 (433.05%) | |
| Low | 18.00 (Goldman Sachs, 283.80%) | Buy |
| Average | 24.50 (422.39%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 4.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 14 May 2025 | 18.00 (283.80%) | Buy | 4.50 |
| Oppenheimer | 14 May 2025 | 22.00 (369.08%) | Buy | 4.50 |
| HC Wainwright & Co. | 28 Apr 2025 | 30.00 (539.66%) | Buy | 4.89 |
| JP Morgan | 28 Mar 2025 | 28.00 (497.01%) | Buy | 4.11 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |